2024 Here we go again., page-210

i wasnt around here in 2016 but there was results posted for phase 2 diabetic trial in october. then in november gvhd phase 3 trial passed interim futility.
im guessing gvhd became the focus not because of poor data for diabetics ( results were significant even though trial was not powered for significance) but because gvhd was more advanced and maybe for some other reasons like greater unmet need. im wondering if this might be an example where insurers would cover "off label" use for kidney failure . we would be competing with ozempics relatively modest 24% reduction in death/mace compared to some of our survival rates.